This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG)
Enrolling by invitation
Conditions studied: Anti MAG Neuropathy
In brief
Patients treated in the hematology department of the Quimper/Cornouaille Hospital Center for IgM monoclonal gammopathy with anti-MAG and symptomatic peripheral neuropathy often reach a therapeutic impasse. The treatment of neuropathic pain is complex, but recently a new non-pharmacological therapy, photobiomodulation, has shown evidence of efficacy and improved quality of life in the treatment of these peripheral neuropathies. This new therapy uses low-intensity lasers; it is non-invasive, athermic, and has no reported side effects. The general principle is to expose tissues to visible light in the red and near-infrared spectrum to elicit a biological response. The study aims to evaluate the efficacy and tolerability of photobiomodulation in this population of patients with anti-MAG neuropathy.
Key facts
- Study ID
- NCT07661667
- Run by
- Centre Hospitalier de Cornouaille
- People needed
- 10
- Starts
- 2026-06-09
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-06-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- IgM gammopathy with the presence of anti-MAG antibodies
- symptomatic peripheral neuropathy
- patient agreement
You may not qualify if…
- Patients with a solid tumor located in areas exposed to PBM
- Patients under legal guardianship (guardianship, conservatorship...)
- cognitive disorders
- Peripheral neuropathy of other aetiologies
- Declining to participate
Where it is running
- Centre hospitalier de Cornouaille — Quimper, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.